Search PubMed⌕ Search

Biomedical subjects

S Takeuchi

Publications and source records attributed to S Takeuchi.

At least 721 records · Page 40Linked to original sources
PubMed1985

[Effects of prostacyclin on the cardiac functions and energy metabolism in the perfused rat heart].

Recently, prostacyclin (PGI2) has been reported to have a role of potential importance in myocardial ischemia. The direct effects of PGI2 on ischemic myocardial injury (60 minutes ischemia at 30 degrees C) were examined, using a hemoglobin free isolated rat heart perfused by the Langendorff's technique. Dual-wavelength reflectance spectrophotometry was used to measure myoglobin oxygenation in cardiac tissue, from which the intracellular oxygen concentration was calculated. The effect of PGI2 on cardial function under normoxic perfusion condition was studied. PGI2 was infused for 10 minutes with the doses of 5ng/g X body weight per minute. PGI2 infusion increased heart rate, LV dp/dt and myocardial oxygen consumption. The average 9.7% increase in myoglobin oxygenation was noted during PGI2 infusion which indicated the improvement in tissue oxygen metabolism. The global ischemia was produced for 60 minutes at 30 degrees C, following to the pretreatment of 10 minutes infusion of PGI2, by the discontinuation of Langendorff's perfusion. Recovery of cardiac function such as double product and LV dp/dt at 15 minutes after reperfusion was significantly higher in the PGI2 treated group than in hearts receiving only the vehicle. Infusion of PGI2 inhibited the decrease in ATP level of the ischemic myocardium at 15 minutes after reperfusion (P less than 0.025, P less than 0.05). PGI2 prevented the increase in lactate release from the ischemic myocardium, observed in vehicle group at 1 minutes after reperfusion. In summary, prostacyclin seems to have a direct cytoprotective effect on ischemic myocardium.

Animals↗
PubMed1985

[Clinical study of recombinant interferon alpha-2 (Sch 30500) in advanced gynecological cancers].

Recombinant interferon alpha-2 (Sch 30500) was administered to 29 patients with advanced gynecological cancers (14 patients with cancer of the cervix, 8 with ovarian cancer, 4 with uterine sarcoma, 2 with endometrial cancer and 1 with unclassified cancer). No antitumor effects (CR and PR) were noted in 23 evaluable patients. Side effects observed were fever, tachycardia, diarrhea, chills, general fatigue, anorexia, nausea and vomiting. In some patients, leukopenia, decrease of hemoglobin and elevation of SGOT and SGPT were observed. No production of antibody for Sch 30500 was noted.

Adult↗
PubMed1985

[HLA antigen on the trophoblast of normal pregnancy].

The mechanism of fetal survival as a semiallograft in the uterus remains to be clarified. In this context, the expression of HLA antigen on the trophoblast which stands between the mother and the fetus is the main problem, because HLA antigen plays an important role in immunological reaction to an allograft. For this purpose, 41 pregnant uteri (6-18 weeks of gestation) were examined immunohistochemically (avidin-biotin-peroxidase complex method) using monoclonal antibodies to HLA antigens. Troma 1, a rat monoclonal antibody, was used as a trophoblast marker in immunohistochemical studies. The results were as follows: HLA-A,B,C is not expressed on syncytiotrophoblast and villous cytotrophoblast. HLA-A,B,C is expressed on nonvillous cytotrophoblast which exists in cytotrophoblastic cell column, cytotrophoblastic shell, and endometrium. HLA-DR is not expressed on any trophoblast. The absence of HLA antigen on syncytiotrophoblast and villous cytotrophoblast seems to be essential for the survival of the fetus. But it is proved that some trophoblasts express HLA-A,B,C on their cell surface and they are adjacent to endometrial cells or maternal blood. From these findings, it seems that fetal HLA antigen might be recognized by the mother and there might be an exquisite immune escape mechanism in decidua.

Antibodies, Monoclonal↗
PubMed1985

Immuno-histological localization of tissue polypeptide antigen (TPA) in gynecological malignancies.

The presence of Tissue Polypeptide Antigen (TPA) was demonstrated by immunohistochemical techniques in various specimens of gynecological malignancies as well as uterine precancerous lesions and trophoblastic disease. In 82 cases, the overall positive rate for staining was 49%. The relationship between the histological progress of malignancy and the positive rate for TPA was not confirmed, nor was the positive rate directly proportional to the histological typings. A serum TPA level of 160 U/l was considered to be the critical level of immunohistological positivity.

Adenocarcinoma↗
PubMed1985

[Effect, toxicity and tissue concentration in the clinical use of cis-diamminedichloroplatinum (II)].

The tissue cis-diamminedichloroplatinum (II) (CDDP) concentration was measured in autopsies treated with CDDP therapy for gynecological malignancies. These cases consisted of 10 of ovarian tumor and one of choriocarcinoma. Total CDDP doses administered were from 55mg to 560mg and among them three cases were treated with more than 500mg (525mg, 555mg in ovarian cancer and 560mg in choriocarcinoma). We found moderate renal impairment with this drug by serum functional test and histopathology, although these changes did not correspond with the total doses. In liver, kidney and residual tumor measured for CDDP, the tissue concentration was highest in liver. When total doses administered were compared with the tissue concentration in liver, kidney, residual tumor and the decrease in creatinine clearance value, there were statistically significant differences only in residual tumor at p less than 0.01.

Adult↗
PubMed1985

[Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer].

We conducted a joint phase II study in 76 patients with gynecological cancer (42 patients with ovarian cancer, 22 patients with cervical cancer, 10 patients with endometrial cancer and 2 patients with vaginal cancer). The response rate was 25.0% in the patients with ovarian cancer, 13.3% in those with cervical cancer, and 28.6% in those with endometrial cancer. The overall response rate was 23.1%. When the patients were classified according to dose schedules, the highest response rate was obtained in the group administered THP-ADM at a dose of 60 mg per body by single i.v. injection at 3-week intervals. Such side effects as myelosuppression and gastrointestinal disturbances were observed, but alopecia, a marked side-effect of ADM administration, was mild, and no cardiac toxicity was seen in any of the patients.

Adult↗
PubMed1985

[On interrupted postmolar choriocarcinoma].

It is extremely difficult to specify which pregnancy is responsible for gestational choriocarcinoma. Generally an antecedent pregnancy, directly preceding choriocarcinoma, is thought to be responsible for it. We have seen not a few cases of choriocarcinoma that had an obstetrical history of previous molar pregnancy preceding antecedent pregnancy. In such cases, responsibility not of the antecedent non-molar pregnancy but of the previous molar pregnancy is highly suspect in choriocarcinoma. In Niigata prefecture which has a population of 2.5 millions, we have reported 1,573 cases of total hydatidiform mole and 61 cases of choriocarcinoma in the past 12 years to the Regional Trophoblastic Disease Center. There were 8 cases of interrupted postmolar choriocarcinoma. The antecedent pregnancy was term delivery in 6 cases and abortion in 2 cases. It was of special interest to note that most of the interrupted postmolar choriocarcinoma were anteceded by term delivery with a previous history of hydatidiform mole. With the aid of statistics of pregnancy, delivery and trophoblastic disease in Niigata prefecture in the period of the survey, delivery with a previous history of hydatidiform mole was calculated to have 290 times as high risk of choriocarcinoma as that without a history of hydatidiform mole. Recently intraplacental choriocarcinoma with either living or, at times, stillborn baby has been reported occasionally. Most of the placenta reported in those cases showed no adverse effect on the growth of the fetus and no gross abnormality. Mostly intraplacental choriocarcinomatous lesion was detected incidentally or by minute histological examination of the placenta. From these results we emphasize the need to have a careful gross as well as microscopic examination of the placenta in case of a parturient with a previous history of hydatidiform mole and who has a higher risk for choriocarcinoma.

Adult↗
PubMed1985

[On the results of hydatidiform mole managed by Niigata method].

We have managed 518 cases of total mole patients in our Ob-Gyn clinic in the past 13 years by the Niigata postmole management method. Serial urinary hCG determination by sensitive assay (Higonavis and RIA) is the key examination in it. There are two critical points of urinary hCG determination: 1,000iu/L at the 5th week and 100iu/L at the 8th week after the termination of hydatidiform mole. The urinary hCG patterns are classified into type I if the hCG regression curve falls below both of them, and into type II if it follows curves other than type I. Among 89 cases of postmole patients who were administered no anti-cancer chemotherapy, 73 cases (82%) showed a type I hCG regression pattern, eight cases of which (11%) were complicated mole such as metastatic mole and invasive mole. Sixteen cases (18%) showed type II, but 8 of them (50%) were diagnosed as uncomplicated mole. The rate of complication among 118 cases of hydatidiform mole who had a molar pregnancy terminated and were followed up totally in our clinic was 24.6% and that of referral cases after molar evacuation was 21.3%, which is significantly higher than others reported in literature. There occurred no postmolar choriocarcinoma from uncomplicated mole patients who had their LH level confirmed in their urinary hCG determination, but 1 case (2.7%) did occur from LH level confirmed metastatic mole, and 3 cases (3.9%) from LH level confirmed metastatic invasive mole. It was shown that lung shadows on chest roentgenogram mostly take about 40 days to appear after D & C of hydatidiform mole and after surgery for uterine invasive mole.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1984

A direct evidence for defect in glucose-6-phosphate transport system in hepatic microsomal membrane of glycogen storage disease type IB.

Uptake of glucose-6-phosphate by microsomes of hepatocyte in rats, human controls and patients with glycogen storage disease type Ia and Ib was studied. In rat the uptake of glucose-6-phosphate increased rapidly and reached to a plateau, but mannose-6-phosphate was not accumulated. These findings indicate that a glucose-6-phosphate specific transport system exists in the microsomal membrane. In human controls and patients with glycogen storage disease type Ia the uptake of glucose-6-phosphate was clearly observed. On the other hand, no accumulation of it was detected in a patient with glycogen storage disease type Ib. These data provide a direct evidence of the defect in the glucose-6-phosphate transport system of hepatic microsomal membrane in glycogen storage disease type Ib.

Animals↗
PubMed1984

Mixed mesodermal tumor of the ovary with carcinoembryonic antigen and alkaline phosphatase production. Histochemical, autoradiographic, and electron microscopic studies of heterotransplanted tumors in athymic nude mice.

A mixed mesodermal tumor of the ovary with carcinoembryonic antigen (CEA) and alkaline phosphatase (ALP) production was serially heterotransplanted into nude mice. The original tumor was diagnosed as homologous tumor, with sarcomatous component consisting of nonspecific spindle-shaped cells. These features were basically retained in the transplanted tumors, including CEA and ALP production. But, heterologous, chondrocytic-differentiated foci were found in the tumors at the third and sixth passages. Transitional-type cells from sarcomatous to carcinomatous cells were sometimes found in the transplanted tumors by light and electron microscopy. Ciliated sarcomatous cells, which may also represent the epithelial differentiation of sarcomatous cells, were found in the tumors at first passage. The current results support the combination tumor theory, which means that both the carcinomatous and sarcomatous components are of common stem cell origin.

Alkaline Phosphatase↗